# A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis

> **NCT02603172** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 23 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** GSK3039294

## Key facts

- **NCT ID:** NCT02603172
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-12
- **Primary completion:** 2017-05-10
- **Final completion:** 2017-05-10
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** A new study will be initiated in order to specifically investigate cardiac safety
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603172, "A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02603172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*